192 related articles for article (PubMed ID: 32828383)
1. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.
Feng CH; Mell LK; Sharabi AB; McHale M; Mayadev JS
Semin Radiat Oncol; 2020 Oct; 30(4):273-280. PubMed ID: 32828383
[TBL] [Abstract][Full Text] [Related]
2. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the Treatment of Cervical Cancer with Bulky Pelvic Lymph Nodes: An Overview of the Current Evidence.
Tohyama A; Murakami M; Yoshino K
J UOEH; 2020; 42(4):317-325. PubMed ID: 33268608
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.
Robin TP; Amini A; Schefter TE; Behbakht K; Fisher CM
Brachytherapy; 2016; 15(6):845-850. PubMed ID: 27720204
[TBL] [Abstract][Full Text] [Related]
6. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
7. Pathological Risk Factors and Outcomes in Women With Stage IB2 Cervical Cancer Treated With Primary Radical Surgery Versus Chemoradiotherapy.
Bradbury M; Founta C; Taylor W; Kucukmetin A; Naik R; Ang C
Int J Gynecol Cancer; 2015 Oct; 25(8):1476-83. PubMed ID: 26244756
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
9. ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology.
Gaffney DK; Erickson-Wittmann BA; Jhingran A; Mayr NA; Puthawala AA; Moore D; Rao GG; Small W; Varia MA; Wolfson AH; Yashar CM; Yuh W; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):609-14. PubMed ID: 21215531
[No Abstract] [Full Text] [Related]
10. Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.
Xiang M; Kidd EA
J Natl Compr Canc Netw; 2019 Aug; 17(8):969-975. PubMed ID: 31390586
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
12. [Current methods of chemoradiotherapy for locally advanced cervical cancer. Options for reduction of side-effects].
Póti Z; Mayer A
Orv Hetil; 2013 May; 154(21):803-9. PubMed ID: 23692874
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.
Roszik J; Ring KL; Wani KM; Lazar AJ; Yemelyanova AV; Soliman PT; Frumovitz M; Jazaeri AA
Front Immunol; 2018; 9():2102. PubMed ID: 30283446
[TBL] [Abstract][Full Text] [Related]
14. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy: results from a single institution.
Khalil J; El Kacemi H; Afif M; Kebdani T; Benjaafar N
Arch Gynecol Obstet; 2015 Nov; 292(5):1091-9. PubMed ID: 25914074
[TBL] [Abstract][Full Text] [Related]
15. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and targeted therapy for cervical cancer: an update.
Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
[TBL] [Abstract][Full Text] [Related]
17. Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer--from the large database of 46,313 cases of cervical cancer in China.
Li W; Liu P; Zhao W; Yin Z; Lin Z; Bin X; Lang J; Chen C
Eur J Surg Oncol; 2020 Jan; 46(1):148-154. PubMed ID: 31623897
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers.
Chantalat E; Vidal F; Leguevaque P; Lepage B; Mathevet P; Deslandres M; Motton S
Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():118-22. PubMed ID: 26295788
[TBL] [Abstract][Full Text] [Related]
19. Role of metastasectomy and chemotherapy in carcinoma of uterine cervix.
Ali N; Mansha MA; Abbasi AN; Qureshi BM
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28768676
[TBL] [Abstract][Full Text] [Related]
20. Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol.
Wang Y; Ouyang Y; Su J; Liu J; Cai Q; Xu Q; Bai Z; Cao X
BMJ Open; 2019 Oct; 9(10):e028171. PubMed ID: 31594870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
